Ticker Symbol will remain "NBS"
NeoStem (NBS) will move its listing from NYSE MKT to the NASDAQ Capital Market effective with the start of trading on 8/5/13. NeoStem will continue to trade under its existing ticker symbol "NASDAQ: NBS". NeoStem's common stock will continue to trade as NYSE MKT: NBS until the market close on 8/2/13.
The Bottom Line: The NASDAQ will provide enhanced institutional and retail <the old adage of above $5> exposure and better trading. NBS will join comparable cell therapy and regenerative medicine companies: Celgene Corporation (CELG), Harvard Bio (HBIO), Osiris (OSIR), Mesoblast ADR (MBLTY), bluebird bio (BLUE), Stemline (STML), Verastem (VSTM), Wright-Medical (WMGI), Shire ADR (SHPG) and Cytori (CYTX) on the NASDAQ.
NBS closed at $7.47 … UP +$0.82 or +12.33% on strong volume of 663.6 K. As I had been stating NBS has been hitting to right field with 2 and 3 solid base hits. The key after any reverse is the keep swinging with base hits and NBS is delivering for the cell therapy sector. NBS is one of the few with positive catalysts - that stay in the <universe> park and we are only in the second inning with multiple batters on deck and base runners on 1st and 3rd.
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.